Results 11 to 20 of about 1,113 (191)

Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review [PDF]

Ophthalmology and Therapy, 2018
Diabetic macular edema (DMO) is a leading cause of blindness in the working age population. Although anti-vascular endothelial growth factor (VEGF) therapy provided a major advance in treatment of DMO for many patients, there is a significant proportion ...
Rupal Morjaria, Alastair K Denniston
exaly   +5 more sources

Intravitreal Therapy for Diabetic Macular Edema: An Update [PDF]

Journal of Ophthalmology, Volume 2021, Issue 1, 2021., 2021
Diabetic macular edema (DME) represents a prevalent and disabling eye condition. Despite that DME represents a sight-Threatening condition, it is also among the most accessible to treatment.
Alessio G., Boscia F., Furino C., Reibaldi M.   +3 more
core   +2 more sources

Off-Label Use of 0.19 mg Fluocinolone Acetonide Intravitreal Implant: A Systematic Review

Journal of Ophthalmology, 2021
Corticosteroids are used in a variety of ophthalmological diseases. One challenge faced by ophthalmologists is to deliver corticosteroids to the posterior segment of the eye with efficacy and safety.
Flávio Ribeiro, Manuel S. Falcão
doaj   +2 more sources

Anti-CD20 therapy for multiple sclerosis-associated uveitis: A case series [PDF]

European Journal of Neurology, Volume 29, Issue 10, Page 3028-3038, October 2022., 2022
Background and purpose: Approximately 1% of patients with multiple sclerosis (MS) have uveitis, but data on the effects of immunotherapies for MS on MS-associated uveitis are scarce.
Meisel, Andreas, Otto, Carolin, Pleyer, Uwe, Ruprecht, Klemens, Rübsam, Anne, Stascheit, Frauke   +5 more
core   +2 more sources

Micro-implant d'acétonide de fluocinolone (ILUVIEN(®)) pour l'oedème maculaire diabétique chronique [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema]. [PDF]

Journal Français d'Ophtalmologie, 2015
Diabetic macular edema (DME) is a frequent complication of diabetic retinopathy and may cause severe visual loss. In this article, we examine the pathophysiology of DME and review various treatment options, such as laser photocoagulation, anti-vascular ...
Behar-Cohen, F., Soubrane, G.
core   +4 more sources

Long-term outcomes of intravitreal 0.19 mg fluocinolone acetonide implant in uveitic macular edema after prior local corticosteroid treatments [PDF]

Journal of Ophthalmic Inflammation and Infection
Background This study evaluates the long-term efficacy and safety of intravitreal 0.19 mg fluocinolone acetonide implant (FAi) in non-infectious UME, comparing it with prior sub-Tenon’s triamcinolone acetonide (STTA) and/or intravitreal dexamethasone ...
Ana Margarida Ferreira, Marta Inês Silva, Sónia Torres-Costa, Cláudia Oliveira-Ferreira, Ana Catarina Pedrosa, Luís Figueira, Joana Rodrigues Araújo   +6 more
doaj   +2 more sources

Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study [PDF]

Frontiers in Pharmacology
BackgroundCorticosteroids are extensively used in ophthalmology, particularly for treating various inflammatory conditions. Despite their effectiveness, prolonged or high-dose corticosteroid use is associated with significant adverse drug reactions (ADRs)
Chengzhi Liu, Xinyu Wang, Xusheng Cao
doaj   +2 more sources

The effectiveness of the 0.19 mg fluocinolone acetonide implant in treating non-infectious posterior uveitis: a real-world experience [PDF]

Journal of Ophthalmic Inflammation and Infection
Background The 0.19 mg fluocinolone acetonide (FAc) implant (ILUVIEN) has been approved for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
Igor Kozak, Avinash Gurbaxani, Maya Pandova   +2 more
doaj   +2 more sources

Fluocinolone acetonide 0.2 µg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations [PDF]

Journal of Ophthalmic Inflammation and Infection
Background Non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) is an inflammatory disease, which can significantly impair visual acuity if not adequately treated.
Uwe Pleyer, Carlos Pavesio, Elisabetta Miserocchi, Carsten Heinz, Helen Devonport, Víctor Llorenç, Tomás Burke, Vanda Nogueira, Laurent Kodjikian, Bahram Bodaghi   +9 more
doaj   +2 more sources

Fluocinolone Acetonide Implant for Uveitis: Dissecting Responder and Non-Responder Outcomes at a Tertiary Center [PDF]

Biomedicines
Macular edema (ME) remains a primary cause of visual deterioration in uveitis. Visual acuity (VA) can often be maintained using corticosteroid depot systems.
Jasmin Abu Arif, Vitus André Knecht, Anne Rübsam, Vanessa Lussac, Zohreh Jami, Dominika Pohlmann, Bert Müller, Uwe Pleyer   +7 more
doaj   +2 more sources